Increased SRC activity and enhanced EGFR phosphorylation at Y845 has been observed in cetuximab-resistant CRC cells, whereas inhibition of SRC activity sensitizes cells to cetuximab treatment [36]. The gene discussed is SRC; the disease is colorectal carcinoma.